Reapplix
Founded 2008 · 42 employees on LinkedIn · 1 known investors
Reapplix develops the 3C Patch System, which uses a small sample of a patient's own blood to produce an autologous patch of proteins, active cells and growth factors applied at point-of-care. The device is used as an adjunctive treatment to accelerate healing of hard-to-heal diabetic foot ulcers.
Investors · 1
Frequently asked questions
- What does Reapplix do?
- Reapplix develops the 3C Patch System, which uses a small sample of a patient's own blood to produce an autologous patch of proteins, active cells and growth factors applied at point-of-care. The device is used as an adjunctive treatment to accelerate healing of hard-to-heal diabetic foot ulcers.
- Who are Reapplix's investors?
- Reapplix's investors include Lauxera Capital Partners.